CAG方案治疗低增生性急性髓系白血病临床分析

Chemotherapy with CAG regimen to patients with hypoplastic acute myeloid leukemia

目的探讨CAG方案对低增生性急性髓系白血病治疗的疗效。方法分析低增生性急性髓系白血病住院患者52例,采用阿糖胞苷和阿克拉霉素联合粒细胞集落刺激因子(CAG)方案治疗并长期随访。结果CAG方案对低增生性急性髓系白血病的总有效率为79%,完全缓解(CR)率56%,部分缓解(PR)率28%,达CR者中生存期和无病生存期为14个月和7个月,PR和未缓解(NR)者中生存期分别为6个月和4个月。主要毒副作用是骨髓抑制,其他非血液学毒性表现轻微。结论CAG方案对低增生性急性髓系白血病患者有积极的治疗作用,副作用少,值得推广。

Objective To investigate the efficacy of chemotherapy with CAG regimen to patients with hypoplastic acute myeloid leukemia （AML）. Methods The patients with hypoplastic acute myeloid leukemia （ n = 52） were treated with CAG regimen and followed-up for a long-time. Results The total effective rate, complete remission （CR） and partial remission （PR） in patients with CAG regimen of hypoplastic AML were 79%, 56% and 28%, respectively. The median survival and disease-free survival of CR patients were 14 month and 7 month, and the median survival of PR and NR patients were 6 month and 4 month respectively. Bone marrow suppression was the common side effect, other non-hematologic toxicity was mild. Conclusion CAG regmen is effective to patients with hypoplastic AML and side effect is mild.